Food preferences may shift, with some individuals experiencing reduced cravings for high-fat or high-sugar foods
This comparative perspective juxtaposes the two compounds with respect to molecular pharmacology, clinical efficacy, safety, and potential clinical positioning, and proposes that, because resmetirom primarily targets hepatic lipid disposal whereas semaglutide unloads systemic caloric pressure, their complementary actions could be harnessed sequentially or in combination to achieve broader, more durable disease modification across the heterogeneous spectrum of patients with MASH
First used as a type 2 diabetes medication, it lowers levels of sugar in the blood
Some patients achieved greater than 30% weight loss , rivaling bariatric surgery
More serious complications require immediate medical attention and occur in less than certain patients